Asbestos and erionite prime and activate the NLRP3 inflammasome that stimulates autocrine cytokine release in human mesothelial cells

Particle and Fibre Toxicology

Volumn 10, Issue 1, 2013, Pages 1-14

  Hillegass, Jedd M ^a   Miller, Jill M ^a   MacPherson, Maximilian B ^a   Westbom, Catherine M ^a   Sayan, Mutlay ^a   Thompson, Joyce K ^a   Macura, Sherrill L ^a   Perkins, Timothy N ^a   Beuschel, Stacie L ^a   Alexeeva, Vlada ^a   Pass, Harvey I ^b   Steele, Chad ^c   Mossman, Brooke T ^a   Shukla, Arti ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

Asbestos; Inflammasomes; Mesothelioma; Mesothelium; NLRP3

Indexed keywords

ASBESTOS; CRYOPYRIN; ERIONITE; INDUSTRIAL CHEMICAL; INFLAMMASOME; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; VASCULOTROPIN; AUTACOID; CARRIER PROTEIN; CROCIDOLITE; CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MESSENGER RNA; NLRP3 PROTEIN, HUMAN; ZEOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVATION; ENZYME ACTIVITY; FEEDBACK SYSTEM; FIBER; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALIGNANT MESOTHELIOMA; MESOTHELIUM CELL; MOUSE; NONHUMAN; PLEURAL FIBROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANIMAL; AUTOCRINE EFFECT; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; EPITHELIUM; GENETICS; IMMUNOLOGY; MESOTHELIOMA; METABOLISM; PATHOLOGY; PRIMARY CELL CULTURE; SCID MOUSE; TIME; TUMOR CELL LINE;

ANIMALS; ASBESTOS, CROCIDOLITE; AUTOCRINE COMMUNICATION; CARRIER PROTEINS; CELL LINE, TUMOR; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIUM; HUMANS; INFLAMMASOMES; INFLAMMATION MEDIATORS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MESOTHELIOMA; MICE; MICE, SCID; PRIMARY CELL CULTURE; RECEPTORS, INTERLEUKIN-1; RNA, MESSENGER; TIME FACTORS; TRANSCRIPTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS; ZEOLITES;

EID: 84882604061     PISSN: None     EISSN: 17438977     Source Type: Journal    
DOI: 10.1186/1743-8977-10-39     Document Type: Article

References (45)

1. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005, 353:1591-1603. 10.1056/NEJMra050152, 16221782.
2. Mossman BT, et al. Asbestos: scientific developments and implications for public policy. Science 1990, 247:294-301. 10.1126/science.2153315, 2153315.
3. Heintz NH, Janssen-Heininger YM, Mossman BT. Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways. Am J Respir Cell Mol Biol 2010, 42:133-139. 10.1165/rcmb.2009-0206TR, 2822975, 20068227.
4. American Thoracic Society Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med 2004, 170:691-715. American Thoracic Society.
5. Mossman BT, Churg A. Mechanisms in the pathogenesis of asbestosis and silicosis. Am J Respir Crit Care Med 1998, 157:1666-1680. 10.1164/ajrccm.157.5.9707141, 9603153.
6. Mossman BT, et al. Pulmonary endpoints (lung carcinomas and asbestosis) following inhalation exposure to asbestos. J Toxicol Environ Health B Crit Rev 2011, 14:76-121. 10.1080/10937404.2011.556047, 3118517, 21534086.
7. Dostert C, et al. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008, 320:674-677. 10.1126/science.1156995, 2396588, 18403674.
8. Broaddus VC, et al. Non-neoplastic and neoplastic pleural endpoints following fiber exposure. J Toxicol Environ Health B Crit Rev 2011, 14:153-178. 10.1080/10937404.2011.556049, 3118521, 21534088.
9. Eisenbarth SC, Flavell RA. Innate instruction of adaptive immunity revisited: the inflammasome. EMBO Mol Med 2009, 1:92-98. 10.1002/emmm.200900014, 3378119, 20049709.
10. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009, 27:229-265. 10.1146/annurev.immunol.021908.132715, 19302040.
11. Baris I, et al. Epidemiological and environmental evidence of the health effects of exposure to erionite fibres: a four-year study in the Cappadocian region of Turkey. Int J Cancer 1987, 39:10-17. 10.1002/ijc.2910390104, 3025107.
12. Hillegass JM, et al. Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model. Ann N Y Acad Sci 2010, 1203:7-14. 10.1111/j.1749-6632.2010.05554.x, 2936775, 20716277.
13. Wang Y, et al. Interleukin-1beta and tumour necrosis factor-alpha promote the transformation of human immortalised mesothelial cells by erionite. Int J Oncol 2004, 25:173-178.
14. Goldberg JL, et al. Novel cell imaging techniques show induction of apoptosis and proliferation in mesothelial cells by asbestos. Am J Respir Cell Mol Biol 1997, 17:265-271. 10.1165/ajrcmb.17.3.2991, 9308911.
15. Driscoll K, et al. Tumour necrosis factor (TNF): Evidence for the role of TNF in increased expression of manganese superoxide dismutase after inhalation of mineral dusts. Ann Occup Hyg 1994, 38:375.
16. Driscoll KE, et al. TNF alpha and increased chemokine expression in rat lung after particle exposure. Toxicol Lett 1995, 82-83:483-489.
17. Shukla A, et al. Alterations in gene expression in human mesothelial cells correlate with mineral pathogenicity. Am J Respir Cell Mol Biol 2009, 41:114-123. 10.1165/rcmb.2008-0146OC, 2701958, 19097984.
18. Lamkanfi M, et al. Inflammasome-dependent release of the alarmin HMGB1 in endotoxemia. J Immunol 2010, 185:4385-4392. 10.4049/jimmunol.1000803, 3428148, 20802146.
19. Entezari M, et al. Inhibition of high-mobility group box 1 protein (HMGB1) enhances bacterial clearance and protects against Pseudomonas Aeruginosa pneumonia in cystic fibrosis. Mol Med 2012, 18:477-485. 3356431, 22314397.
20. Yang H, et al. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci U S A 2010, 107:12611-12616. 10.1073/pnas.1006542107, 2906549, 20616036.
21. Sha Y, et al. HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J Immunol 2008, 180:2531-2537.
22. Schwarznau A, et al. IL-1beta receptor blockade protects islets against pro-inflammatory cytokine induced necrosis and apoptosis. J Cell Physiol 2009, 220:341-347. 10.1002/jcp.21770, 2890273, 19334038.
23. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012, 11:633-652. 10.1038/nrd3800, 3644509, 22850787.
24. Hillegass JM, et al. Utilization of gene profiling and proteomics to determine mineral pathogenicity in a human mesothelial cell line (LP9/TERT-1). J Toxicol Environ Health A 2010, 73:423-436. 10.1080/15287390903486568, 2838458, 20155583.
25. Li H, Ambade A, Re F. Cutting edge: Necrosis activates the NLRP3 inflammasome. J Immunol 2009, 183:1528-1532. 10.4049/jimmunol.0901080, 19596994.
26. Wagner JC, et al. Erionite exposure and mesotheliomas in rats. Br J Cancer 1985, 51:727-730. 10.1038/bjc.1985.108, 1977068, 2986668.
27. Carbone M, et al. Erionite exposure in North Dakota and Turkish villages with mesothelioma. Proc Natl Acad Sci U S A 2011, 108:13618-13623. 10.1073/pnas.1105887108, 3158231, 21788493.
28. Bryant C, Fitzgerald KA. Molecular mechanisms involved in inflammasome activation. Trends Cell Biol 2009, 19:455-464. 10.1016/j.tcb.2009.06.002, 19716304.
29. Janssen YM, et al. Asbestos induces nuclear factor kappa B (NF-kappa B) DNA-binding activity and NF-kappa B-dependent gene expression in tracheal epithelial cells. Proc Natl Acad Sci U S A 1995, 92:8458-8462. 10.1073/pnas.92.18.8458, 41176, 7667311.
30. Janssen YM, et al. Asbestos causes translocation of p65 protein and increases NF-kappa B DNA binding activity in rat lung epithelial and pleural mesothelial cells. Am J Pathol 1997, 151:389-401. 1858001, 9250152.
31. Zanella CL, et al. Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor. Cancer Res 1996, 56:5334-5338.
32. Tanaka T, et al. Induction of VEGF gene transcription by IL-1 beta is mediated through stress-activated MAP kinases and Sp1 sites in cardiac myocytes. J Mol Cell Cardiol 2000, 32:1955-1967. 10.1006/jmcc.2000.1228, 11040101.
33. Weber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) pathway. Sci Signal 2010, 3:cm1. 10.1126/scisignal.3105cm1, 20086235.
34. Adachi Y, et al. Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas. Int J Cancer 2006, 119:1303-1311. 10.1002/ijc.22006, 16642474.
35. Minogue AM, Barrett JP, Lynch MA. LPS-induced release of IL-6 from glia modulates production of IL-1 beta in a JAK2-dependent manner. J Neuroinflammation 2012, 9:126. 10.1186/1742-2094-9-126, 3418561, 22697788.
36. Koenen TB, et al. The inflammasome and caspase-1 activation: a new mechanism underlying increased inflammatory activity in human visceral adipose tissue. Endocrinology 2011, 152:3769-3778. 10.1210/en.2010-1480, 21862623.
37. Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003, 348:2583-2584. 10.1056/NEJM200306193482523, 12815153.
38. So A, et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007, 9:R28. 10.1186/ar2143, 1906806, 17352828.
39. Zeft A, et al. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. J Clin Rheumatol 2009, 15:161-164. 10.1097/RHU.0b013e3181a4f459, 19363453.
40. Eigenbrod T, et al. Cutting edge: critical role for mesothelial cells in necrosis-induced inflammation through the recognition of IL-1 alpha released from dying cells. J Immunol 2008, 181:8194-8198. 2762646, 19050234.
41. Dickson MA, et al. Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol Cell Biol 2000, 20:1436-1447. 10.1128/MCB.20.4.1436-1447.2000, 85304, 10648628.
42. Pass HI, et al. Characteristics of nine newly derived mesothelioma cell lines. Ann Thorac Surg 1995, 59:835-844. 10.1016/0003-4975(95)00045-M, 7695406.
43. Campbell WJ, Huggins CW, Wylie AG. Chemical and physical characterization of amosite, chrysotile, crocidolite, and nonfibrous tremolite for oral ingestion studies 1980, Washington, DC: U.S. Department of the Interior, U.S. Bureau of Mines, by the National Institute of Environmental Health Sciences.
44. Shukla A, et al. Transcriptional up-regulation of MMP12 and MMP13 by asbestos occurs via a PKCdelta-dependent pathway in murine lung. FASEB J 2006, 20:997-999. 10.1096/fj.05-4554fje, 16571779.
45. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254. 10.1016/0003-2697(76)90527-3, 942051.